Pemvidutide
Obesity
About Altimmune
Altimmune's mission is to develop transformative peptide-based medicines for obesity, liver diseases, and other metabolic disorders. Its strategic pivot from vaccines to metabolic therapeutics is anchored by compelling Phase 2 data for pemvidutide, which showed significant weight loss and resolution of metabolic dysfunction-associated steatohepatitis (MASH). The company's strategy focuses on advancing pemvidutide into late-stage development while leveraging its peptide engineering platform to build a pipeline of targeted multi-agonists.
View full company profileAbout Altimmune
Altimmune's mission is to develop transformative peptide-based medicines for obesity, liver diseases, and other metabolic disorders. Its strategic pivot from vaccines to metabolic therapeutics is anchored by compelling Phase 2 data for pemvidutide, which showed significant weight loss and resolution of metabolic dysfunction-associated steatohepatitis (MASH). The company's strategy focuses on advancing pemvidutide into late-stage development while leveraging its peptide engineering platform to build a pipeline of targeted multi-agonists.
View full company profileOther Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |